YouTube2Text

La Chine prépare une révolution : le médicament — Transcript

by Les Echos · 2,389 words · 399 segments · language en · Watch on YouTube

Full transcript

  1. 0:00Barcelona, September 2024. Ivonicept, a
  2. 0:03new drug tested for lung cancer, is
  3. 0:06causing a seismic shift. For the first
  4. 0:09time, there was a new anticancer drug
  5. 0:12that outperformed the gold-standard
  6. 0:14American drug, Keytruda.
  7. 0:16And in your opinion, where does this
  8. 0:18new drug come from?
  9. 0:19It completely changed the perception of
  10. 0:21China. It was no longer just the
  11. 0:24world's factory copying the West. It
  12. 0:26was becoming the world's brain.
  13. 0:29On its own, ivonicept is the symbol of
  14. 0:31an industry in full transformation:
  15. 0:32biotech. An industry where eyes are
  16. 0:34increasingly turning toward the East,
  17. 0:37which has laboratories for molecule
  18. 0:39research, hospitals for testing,
  19. 0:42factories to manufacture drugs, and
  20. 0:45dormitories to house young doctors.
  21. 0:49Today, between 3,000 and 4,000 Chinese
  22. 0:50biotech firms, 150 of which are
  23. 0:52publicly traded, try every day to
  24. 0:54invent the drugs of tomorrow. And in
  25. 0:562024, for the first time, the majority
  26. 0:58of new molecules discovered globally
  27. 1:00came from China. There
  28. 1:02is an industrial reality, an
  29. 1:04entrepreneurship of Chinese companies
  30. 1:06that are now at the forefront.
  31. 1:08How can we explain this shift, and can
  32. 1:10the United States stop it? My name is
  33. 1:13Harold Grand, I am a video journalist
  34. 1:15at Les Échos, and today I'm taking you
  35. 1:16on a journey into the ultra-strategic
  36. 1:18world of Chinese pharmaceuticals. To
  37. 1:26understand how China carved out a place
  38. 1:28on the global drug map, we must return
  39. 1:31to the basics: the life cycle of a drug
  40. 1:33.
  41. 1:34What matters is the marketing
  42. 1:36authorization, or MA. This is Eric
  43. 1:40Bouteiller, a professor at the China
  44. 1:41Europe International Business School
  45. 1:43and author of a reference book on
  46. 1:45market access for pharmaceutical
  47. 1:46products. He lives in China 7 months a
  48. 1:49year, and he was kind enough to come to
  49. 1:51our air-conditioning-free studio during
  50. 1:53a heatwave while visiting Paris.
  51. 1:55Does that match what you're looking for
  52. 1:56or not?
  53. 1:56Yeah, that's great.
  54. 1:57Marketing authorization. That's what
  55. 2:00counts because from that moment on, you
  56. 2:02have the ability to sell a
  57. 2:04pharmaceutical product.
  58. 2:05Those who sell these pharmaceutical
  59. 2:07products are the laboratories that hold
  60. 2:08the rights via a patent. Sometimes they
  61. 2:11develop their products themselves;
  62. 2:12sometimes they buy this stage from
  63. 2:14other establishments specialized in
  64. 2:16medical research: biotechs. The
  65. 2:19development of a pharmaceutical product
  66. 2:20, in general, is something that takes
  67. 2:22an enormous amount of time. It takes
  68. 2:25about ten years, within a product life
  69. 2:27cycle of around 20 years or so.
  70. 2:31And later on, much later, something
  71. 2:32else happens.
  72. 2:33We enter into what we call the generics
  73. 2:35phase. The laboratory and obviously the
  74. 2:38biotech firm before it will lose all
  75. 2:40rights, and it becomes a product that
  76. 2:42can be manufactured by any generic
  77. 2:44company, provided it obviously complies
  78. 2:46with the pharmaceutical file submitted
  79. 2:48to the authorities.
  80. 2:50If I’m talking to you about generics,
  81. 2:51it’s because that’s the field in
  82. 2:53which China has excelled for decades,
  83. 2:54and it’s what laid the foundations
  84. 2:56for the explosion of biotechs in the
  85. 2:57country. Moreover, it’s the same
  86. 2:59pattern as in tech or the automotive
  87. 3:00industry. China first mastered
  88. 3:01logistics before innovating and
  89. 3:03flooding the market. Take the example
  90. 3:06of BYD, a small battery manufacturer
  91. 3:08that became the number one electric car
  92. 3:11manufacturer in 30 years, ahead of
  93. 3:13Tesla in 2025 with over 1.6 million
  94. 3:16models sold. China has succeeded in
  95. 3:20achieving significant health
  96. 3:22development in its country by
  97. 3:24establishing a generic industry,
  98. 3:26systematic copying, if you will. And it
  99. 3:29spent about twenty years since the
  100. 3:32country's opening, so from the 90s to
  101. 3:352015-16, trying to develop
  102. 3:37pharmaceutical innovation on its own.
  103. 3:41It went from the status of factory of
  104. 3:44the world to the lab of the world.
  105. 3:47Raphaël Baligieri is the Les Échos
  106. 3:48correspondent in China, and a few
  107. 3:50months ago, he spent several days in
  108. 3:52Suzhou, the new city dedicated to the
  109. 3:54medicines of tomorrow. Announced in
  110. 3:58October 2010 by the Central Committee
  111. 4:00of the Chinese Communist Party, the
  112. 4:0212th Five-Year Plan made biotechs one
  113. 4:04of the country's seven strategic
  114. 4:06emerging industries. In other words,
  115. 4:08China is beginning a new battle: that
  116. 4:10of research.
  117. 4:11And when I went to Suzhou recently to
  118. 4:14conduct this investigation on biotechs,
  119. 4:16well, I indeed realized that most of
  120. 4:19the biotechs I interviewed were born
  121. 4:21around 2010. And this is also explained
  122. 4:24, curiously, by the subprime crisis in
  123. 4:26the United States and the financial
  124. 4:28crisis, which actually forced a huge
  125. 4:30number of Chinese scientists who had
  126. 4:32left to pursue careers in the U.S. to
  127. 4:34return to China.
  128. 4:36And as an anecdote, these scientists
  129. 4:37even have a nickname: "sea turtles,"
  130. 4:39because they go back to lay their eggs
  131. 4:40where they were born. Employed in major
  132. 4:43American pharmaceutical labs like
  133. 4:44Pfizer, Merck, or Johnson&Johnson, they
  134. 4:47returned home to found their own
  135. 4:48companies. What was very surprising in
  136. 4:52Suzhou is that I actually did all my
  137. 4:54interviews in English with these
  138. 4:56Chinese scientists who had spent 10 or
  139. 4:5815 years in the U.S. and who had been
  140. 5:00drawn back like that by China, by the
  141. 5:03promise of its investments and public
  142. 5:05support.
  143. 5:07A promise accompanied by concrete
  144. 5:08reforms starting in 2015.
  145. 5:10Before 2015, there was an
  146. 5:13administrative way of operating since
  147. 5:172015-2016. This was coupled with
  148. 5:21top-tier scientific thinking. The
  149. 5:24Chinese drug agency has become one of
  150. 5:26the most scientific agencies in the
  151. 5:28world.
  152. 5:29As a result, marketing authorization
  153. 5:31procedures are speeding up, and more
  154. 5:34local clinical trials are recognized,
  155. 5:36reducing market access for patients by
  156. 5:38several years. Naturally, the entire
  157. 5:41drug manufacturing supply chain is
  158. 5:43entering a new dimension. A
  159. 5:45demonstration in Suzhou, 30 minutes by
  160. 5:47high-speed train from Shanghai, where
  161. 5:49over 650 biotechs have sprouted in a
  162. 5:51few years. What
  163. 5:52is striking, well, it's first of all
  164. 5:54its scale, since it's very large. So
  165. 5:58there are large tree-lined avenues, a
  166. 5:59DNA museum, and in fact, you find
  167. 6:01everything in this park. That is to say
  168. 6:05, there are laboratories for molecular
  169. 6:08research, and hospitals for testing on
  170. 6:11a large number of patients with huge
  171. 6:13amounts of data. There are factories to
  172. 6:17manufacture drugs, and dormitories to
  173. 6:20house young doctors and new recruits.
  174. 6:23Some researchers even told Raphaël
  175. 6:25that when they moved to Suzhou to
  176. 6:26launch their biotech, the authorities
  177. 6:28exempted them from rent for several
  178. 6:30months to give them time to generate
  179. 6:32initial income. And it doesn't stop
  180. 6:34there. The entity managing the
  181. 6:36industrial park, called BioBAY,
  182. 6:38invested the equivalent of 309 million
  183. 6:40euros in 2024 into venture capital
  184. 6:42funds dedicated to the biotech sector.
  185. 6:45You can have offices immediately and
  186. 6:48recruit young Chinese researchers who
  187. 6:50just finished their PhDs in China and
  188. 6:53are available right away for lower
  189. 6:55salaries than in the United States. And
  190. 6:59inevitably, at some point, it pays off.
  191. 7:04Back to Barcelona in late 2024. On the
  192. 7:07sidelines of the annual European
  193. 7:09oncology congress, an American biotech,
  194. 7:11Summit Therapeutics, unveils staggering
  195. 7:13results. One of these drugs, ivonimab,
  196. 7:16[outperforms] Keytruda, the world's
  197. 7:18best-selling drug by value, at 32
  198. 7:20billion dollars in 2025. Developed by
  199. 7:23the American giant Merck, it is the
  200. 7:25benchmark for lung cancer. It presented
  201. 7:28results showing it reduced the risk of
  202. 7:32disease progression and death by 49%
  203. 7:35compared to Keytruda in lung cancer.
  204. 7:38Myriam Chauveau is a journalist at Les
  205. 7:40Échos who covers the pharmaceutical
  206. 7:41sector. Okay, so now you're going to
  207. 7:43say, "Fine, Ivonimab is great, but what
  208. 7:45does it have to do with China?" Well,
  209. 7:47even if Summit Therapeutics holds the
  210. 7:49international marketing rights for the
  211. 7:50drug, this cancer treatment was
  212. 7:52initially developed by a Chinese
  213. 7:53biotech, Akeso. And Akeso’s story
  214. 7:56checks all the boxes for the perfect
  215. 7:58biotech according to Beijing. It was
  216. 7:59founded by Michelle Xia in 2012. This
  217. 8:02Chinese researcher, trained in the UK
  218. 8:04where she earned a PhD in molecular
  219. 8:06biology, honed her skills at Bayer in
  220. 8:08the US before returning to start a
  221. 8:10business in China. And just like that,
  222. 8:12another "sea turtle" returns home. From
  223. 8:14that moment on, it was a buying frenzy.
  224. 8:16Everyone wanted to buy the same thing
  225. 8:18as Ivonescimab. It was a complete
  226. 8:20change in perception of China within
  227. 8:22the pharma sector.
  228. 8:24Even though Western biotechs are in
  229. 8:25great shape at the start of this year
  230. 8:27with over 16 deals exceeding a billion
  231. 8:29dollars, it is China that is attracting
  232. 8:31the most funding. Since January 2026,
  233. 8:34American labs have invested 40 billion
  234. 8:36dollars in Chinese biotechs. That’s
  235. 8:38almost as much as in the entire
  236. 8:402020-2025 period. Chinese research is
  237. 8:42so bankable that some labs are taking
  238. 8:44the gamble of buying licenses for drugs
  239. 8:47that haven't even been tested on
  240. 8:48animals yet. We are talking about the
  241. 8:50preclinical stage. That’s what
  242. 8:52happened in December 2024. Merck
  243. 8:54shelled out 2 billion dollars to secure
  244. 8:57an obesity pill from Rionso Pharma, a
  245. 8:59Chinese lab. Today, you have major
  246. 9:03Western labs buying entire pipelines of
  247. 9:06drug candidates—meaning over a dozen
  248. 9:09drug candidates at once. And obviously,
  249. 9:13those buyouts exceed 10 billion dollars
  250. 9:15, right?
  251. 9:16At the end of May, Pfizer struck a deal
  252. 9:18with Suzhou-based biotech Innovent for
  253. 9:21a total of 10.5 billion dollars. And
  254. 9:23what you really need to understand is
  255. 9:25that it’s not just license purchases
  256. 9:27that are allowing Chinese research to
  257. 9:28thrive today.
  258. 9:29You can outright form a research
  259. 9:32cooperation agreement. That’s
  260. 9:34ultimately what Bristol Myers Squibb (
  261. 9:36BMS) did. They bought 13 drug
  262. 9:39candidates from the Chinese lab Jiangsu
  263. 9:42Hengrui. In reality, they didn’t buy
  264. 9:4613. Jiangsu Hengrui handed over the
  265. 9:50rights to four of its drug candidates.
  266. 9:53The American firm BMS brought in the
  267. 9:56rights to four of its own candidates,
  268. 10:00and the two actually struck a deal to
  269. 10:03co-develop five drug candidates. So,
  270. 10:06it’s no longer just a purchase;
  271. 10:08it’s genuine cooperation. And that
  272. 10:09cooperation can go even further. In
  273. 10:122024, a consortium of American
  274. 10:13financial investors bought four "
  275. 10:15coupefin" drug candidates developed by
  276. 10:17the same Chinese lab.
  277. 10:19And Jiangsu Hengrui received cash for
  278. 10:22the sale of its licenses immediately.
  279. 10:25But above all, Jangu Hang owns 20%of
  280. 10:28the capital of the Hercule company,
  281. 10:30which is the American firm where our
  282. 10:33drug candidate licenses were housed.
  283. 10:36the licenses for his drug candidates.
  284. 10:38So for him, it’s a real financial
  285. 10:40windfall for the future.
  286. 10:41After that, Hercule rebranded as
  287. 10:42Kailera Therapeutics and went public on
  288. 10:45the NASDAQ on April 16, 2026. This IPO
  289. 10:48allowed it to raise a record amount of
  290. 10:50625 million dollars. That’s more than
  291. 10:53the IPO of American giant Moderna,
  292. 10:54notably responsible for one of the
  293. 10:56Covid vaccines. A portion of this money
  294. 10:59is directed straight to the Chinese
  295. 11:00laboratory Diongué, thus funding
  296. 11:02Chinese research. As you can imagine,
  297. 11:04China's rise in power? Well, it makes
  298. 11:06some people sick. We must subject
  299. 11:12agreements reached by pharmaceutical
  300. 11:14companies with China to the same level
  301. 11:16of scrutiny we apply to investors in
  302. 11:18the Chinese technology sector.
  303. 11:21Otherwise, China will continue to
  304. 11:22appropriate American innovation and use
  305. 11:24it to drive our companies and
  306. 11:26industries into bankruptcy. Those are
  307. 11:28the words of John Moolenaar. He is an
  308. 11:29American Republican representative who
  309. 11:31heads a special committee on China. He
  310. 11:34just introduced a bill, the Biotech
  311. 11:36Investment National Security Act, which
  312. 11:38has one goal: hitting Beijing in the
  313. 11:41wallet. His idea: try to curb the
  314. 11:59development of a sector that currently
  315. 12:01depends primarily on private money. In
  316. 12:03France, a little over 12%of GDP is
  317. 12:05spent on health expenditures. In China,
  318. 12:08that figure drops to 7%.
  319. 12:09Today, China, from my point of view,
  320. 12:12does not spend enough on on on on on on
  321. 12:14healthcare. And so that explains why
  322. 12:17you have enormous distortions within
  323. 12:19the healthcare system. But the
  324. 12:22authorities don't want to solve these
  325. 12:24problems, they don't want to invest
  326. 12:26more, and they hope that the US or
  327. 12:28Europe will fund their biotech.
  328. 12:31The government's priority today is
  329. 12:33focused on AI, a sector where the
  330. 12:35Communist Party plans to invest 295
  331. 12:38billion dollars by 2030, and of course
  332. 12:40on defense, with a 239 billion dollar
  333. 12:43budget for the year 2026 alone. I dug
  334. 12:46through reports trying to find the
  335. 12:48budget for biotechs, but I didn't come
  336. 12:49across a precise figure. China
  337. 12:51China is a country with very
  338. 12:53significant strategic goals, and it is
  339. 12:55therefore making considerable
  340. 12:57investments in things that we should
  341. 12:59probably also follow very closely, but
  342. 13:01in any case, they aren't improving the
  343. 13:03health of Chinese patients.
  344. 13:06According to this April 2026 study by
  345. 13:08the BCG firm, only 36%of R&D spending
  346. 13:10in Chinese research depends on the
  347. 13:12government. For the rest, they have to
  348. 13:15find the money elsewhere, from major
  349. 13:16Western laboratories or dedicated
  350. 13:18investment funds.
  351. 13:20And in Suzhou, I met biotech firms that
  352. 13:22, well, took 10 to 15 years before
  353. 13:24bringing their first drugs to market.
  354. 13:27The Chinese state does not have the
  355. 13:29means to irrigate and fund its research
  356. 13:31system. So without license sales to
  357. 13:33Westerners, Chinese research would
  358. 13:35grind to a halt because it lacks the
  359. 13:37money. That is why the United States
  360. 13:39wants to hit them where it hurts, to
  361. 13:40stop feeding the beast and prevent
  362. 13:42Chinese biotech firms from becoming
  363. 13:43financially independent in the long run
  364. 13:45. What do we do if we lose that
  365. 13:47knowledge? Can we count on China in the
  366. 13:49future to recover lost knowledge? In my
  367. 13:51opinion, no. It is not in Chinese
  368. 13:54culture, once knowledge is in China, to
  369. 13:56share it with the competition. China
  370. 13:58tends to kill off its competition
  371. 14:00rather than share with it. The most
  372. 14:01famous story is still the one about
  373. 14:03silkworms in antiquity. When China was
  374. 14:07making a lot of money selling silk to
  375. 14:09the West, it prohibited, on pain of
  376. 14:11death, revealing the secrets of silk
  377. 14:13production to Western buyers; you
  378. 14:15weren't allowed to take silkworms out
  379. 14:18of China, and there were customs
  380. 14:20officers on the Silk Road. If they
  381. 14:23found silkworms in your luggage, you
  382. 14:24were put to death.
  383. 14:26Thank you for watching this analysis of
  384. 14:27Chinese biotech firms all the way to
  385. 14:28the end. If you want to dive deeper,
  386. 14:30I've put the link to the report I cited
  387. 14:31in the video in the description. It is
  388. 14:33technical, but it is fascinating. And I
  389. 14:35am including some links to articles by
  390. 14:36Raphaël and Myriam on the subject. Let
  391. 14:38me know in the comments if you would
  392. 14:40like us to cover more health topics,
  393. 14:41and if so, which specific ones. You can
  394. 14:43also find our videos on Spotify, Apple
  395. 14:45Music, and of course on the Les Échos
  396. 14:47website. Subscribe. I also like
  397. 14:49touching the microphone a bit. I think
  398. 14:50it makes it feel more relaxed, you know
  399. 14:51? A bit what?

About this transcript

This page contains the full transcript of La Chine prépare une révolution : le médicament by Les Echos, generated from the public captions YouTube serves with the video. The transcript has 2,389 words across 399 segments, with the original timestamps preserved so you can click any line to jump to that moment in the embedded player.

What you can do with it

Use the transcript to take notes, quote the speaker, build a study guide, generate a summary with ChatGPT or Claude via the YouTube Summary tool, or export it as a timed subtitle file with YouTube to SRT. You can also re-open it in the transcriber to choose a caption track available on the video.

Free YouTube transcript tool

YouTube2Text is a free YouTube transcript generator — no signup, no daily limit. Paste any YouTube link and get the full transcript instantly, with timestamps, click-to-jump, caption language selection, AI prompts for ChatGPT, Claude, and Gemini, and exports to TXT, SRT, VTT, or Markdown.